← Trials/Trial dossier/NCT00704782

TerminatedPhase 2

Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

An Open-Label Extension Study of Combination Therapy With Dimebon and Donepezil in Patients With Alzheimer's Disease

Lead sponsor

Medivation, Inc.

Asset

Dimebon

Listed sites

Recruiting sites

Enrollment

actual

Study population

Alzheimer’s disease

Key I/E criteria

•Alzheimer's disease•Study partner/caregiver required

Primary endpoint

•Safety of Dimebon in combination with donepezil (Aricept)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDDIM13

NCT IDNCT00704782

Timeline

Milestones

Study start2008-04 (month precision)

Study first posted2008-06-25estimated

Primary completion2010-08actual (month precision)

Study completion2010-08actual (month precision)

Last update posted2015-12-10estimated

Assets

Drug assets

Dimebon

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Alzheimer's disease

•On donepezil (Aricept)

•Caregiver who cares for the patient at least 5 days per week

Exclusion criteria

•Unstable medical illnesses or significant hepatic or renal disease

•Other primary psychiatric or neurological disorders

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

1 endpoint

Primary/protocol endpoint

To assess the safety of Dimebon in combination with donepezil (Aricept)

Time frame:week 6, 9, 12, 26 and every 13 weeks thereafter until study discontinuation

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.